Drug resistance is a major cause of treatment failure in pancreatic cancer. The limited evidence indicates the involvement of miR-455-3p in chemotherapy resistance of cancer. Here we observed by qPCR that miR-455-3p was significantly decreased in pancreatic cancer tissues and cell lines. We then confirmed that the inhibition of miR-455-3p increased cell proliferation and gemcitabine resistance of pancreatic cancer, whereas forced overexpression of miR-455-3p had the opposite effect. Furthermore, we demonstrated that TAZ, which is associated with drug resistance of pancreatic cancer, is a new direct downstream target of miR-455-3p. Our present study suggests that miR-455-3p contributes to cell proliferation and drug resistance in pancreatic cancer cells via targeting TAZ.

耐药性是胰腺癌治疗失败的主要原因。有限的证据表明miR-455-3p参与了癌症的化疗耐药性。在这里，我们通过qPCR观察到，胰腺癌组织和细胞系中miR-455-3p显着降低。然后，我们证实抑制miR-455-3p可以提高胰腺癌的细胞增殖和吉西他滨耐药性，而强制过量表达miR-455-3p则具有相反的作用。此外，我们证明了与胰腺癌耐药性相关的TAZ是miR-455-3p的新的直接下游靶标。我们目前的研究表明，miR-455-3p通过靶向TAZ促进胰腺癌细胞的细胞增殖和耐药性。